Live Breaking News & Updates on Autosomal Dominant Polycystic Kidney Disease

Stay updated with breaking news from Autosomal dominant polycystic kidney disease. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

XORTX Therapeutics Inc (XRTX) Appoints Patrick Treanor to its Board

XORTX Therapeutics Inc (XRTX) Appoints Patrick Treanor to its Board
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Ian-klassen , Patrick-treanor , Vifor-pharma , Anthony-giovinazzo , Nasdaq , Oscient-pharmaceuticals , Kalvista-pharmaceuticals-inc , Johnson , Relypsa-pharmaceuticals , Xortx-therapeutics-inc , Insulet-corporation , Bryant-university

XORTX Welcomes New Member to the Board of Directors

CALGARY, Alberta, Jan. 02, 2024 (GLOBE NEWSWIRE) XORTX Therapeutics Inc. (“ ....

Canada , New-york , United-states , Rensselaer-polytechnic-institute , Toronto , Ontario , Ottawa , Canadians , Canadian , Patrick-treanor , Joe-biden , Joe-oconnor

PYC'S FOURTH DRUG CANDIDATE HAS DISEASE-MODIFYING POTENTIAL IN POLYCYSTIC KIDNEY DISEASE

PYC has developed a new drug candidate for the >5 million people worldwide[1] with Polycystic Kidney Disease (PKD) This drug candidate hasdemonstrated efficacy in human models derived from the kidneys of patients with end-stage renal failure due to PKD[2] PKD is a life-changing disease affecting 1 in every 1,000 people[3] Half of the patient population withPKD will require a kidney transplant by the age of 60 due to the absence of impactful treatment options in this disease[4] PKD represents an addressable market of >US$10 billion p.a. and is an area of major commercial interest for the drug development industry[5] Pre-clinical models suggest that addressing the underlying cause ofPKD (the way that PYC's drug candidate works) could arrest the course of the disease in humans, enabling damaged kidneys to regenerate and restore function[6] PYC plans to accelerate this drug candidate into human trials in ~12 months - pursuing a potential high-velocity path through clinical trials ....

Perth , Western-australia , Australia , Crown-biosciences , Twitter , Human-genetics-research , Linkedin , Drug-administration , Polycystic-kidney-disease , Webinar-friday , Autosomal-dominant-polycystic-kidney-disease , Investigational-new-drug

PYC'S FOURTH DRUG CANDIDATE HAS DISEASE-MODIFYING POTENTIAL IN POLYCYSTIC KIDNEY DISEASE

PYC'S FOURTH DRUG CANDIDATE HAS DISEASE-MODIFYING POTENTIAL IN POLYCYSTIC KIDNEY DISEASE
fnarena.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fnarena.com Daily Mail and Mail on Sunday newspapers.

Perth , Western-australia , Australia , Crown-biosciences , Drug-administration , Linkedin , Twitter , Human-genetics-research , Polycystic-kidney-disease , Webinar-friday , Autosomal-dominant-polycystic-kidney-disease , Investigational-new-drug

PYC'S FOURTH DRUG CANDIDATE HAS DISEASE-MODIFYING POTENTIAL IN POLYCYSTIC KIDNEY DISEASE

PYC'S FOURTH DRUG CANDIDATE HAS DISEASE-MODIFYING POTENTIAL IN POLYCYSTIC KIDNEY DISEASE
vietnamtribune.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from vietnamtribune.com Daily Mail and Mail on Sunday newspapers.

Perth , Western-australia , Australia , Crown-biosciences , Linkedin , Human-genetics-research , Twitter , Drug-administration , Polycystic-kidney-disease , Webinar-friday , Autosomal-dominant-polycystic-kidney-disease , Investigational-new-drug